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from pragmatic trials, and another 4 studies (23.5%) from observational studies. 
The odds ratio for effectiveness versus efficacy being cost-effective was 8.75 (95% 
confidence interval; 0.74 to 103.82). ConClusions: Most CEA studies in asthma 
used efficacy data to inform CEA. Studies using effectiveness data trend toward 
being more likely to disseminate cost-effective findings than those using efficacy 
data. Health policy decision makers should pay attention to the type of “E” evidence 
used in CEAs for accurate interpretation and application.
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objeCtives: A cost-effectiveness model can be populated using mortality rates 
from a period’s life-table or using extrapolations of mortality based on historical 
life-tables. Current decision models use the first method. This simulation study aims 
at identifying the impact of mortality methods used on cost effectiveness analy-
ses. Methods: A simulation study was designed based on a two-state Markov model 
(alive-death) that compared a hypothetical intervention against no intervention. The 
model was populated with age-specific, all-cause mortality probabilities from the 
estimation methods presented above. The mortality extrapolations were estimated 
using a smoothed Lee-Carter method. The model outcomes were incremental costs, 
life-years gained (LYG) and incremental net benefit (INB). The proportional difference 
(PD) of the model outcomes between the two mortality estimation methods was the 
outcome of each simulation. The following parameters were simultaneously varied: 
discounting rate (0- 0.05), intervention effect (relative risk of mortality: 0.9-0.99), age 
at intervention (birth- 80 years old), duration of intervention effect (1 year/10 years/ 
lifelong), duration of intervention administration. Simulations were conducted using 
Canadian life-tables. The impact of each parameter on the simulation outcomes was 
estimated using descriptive and graphical methods. Results: The cohorts’ age and 
the discount level had an important effect on the PD in all outcomes (LYG, incremental 
cost and NHB) The duration of intervention effect and administration were more 
influential on the effect of method on the PD of incremental costs and INB. Large 
variation was observed among the scenarios within parameter values, for the PD of 
all outcomes. ConClusions: When using mortality projection methods, substantial 
differences were observed in CEA model outcomes. Given that the magnitude and the 
direction of the impact of mortality estimation methods on the model outcomes is 
multifactorial, decisions on the mortality estimation method used in economic evalu-
ations should be considered after conducting sensitivity analyses using both methods.
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objeCtives: The objective of this study is to examine the prevalence of chronic 
conditions and their impact on the economic burden among cancer survivors in the 
United States. Methods: Using the 2008-2012 Medical Expenditure Panel Survey 
(MEPS) we identified 8,617 cancer survivors and 111,695 individuals without a his-
tory of cancer. Adjusted predictive margins from multivariable regression were used 
to examine the prevalence of chronic conditions. Direct medical costs were meas-
ured using annual health care expenditures and adjusted means were estimated 
using a two-part model. Indirect morbidity costs were calculated from the lost pro-
ductivity due to employment disability, missed work days, and lost household pro-
ductivity and adjusted means were estimated using multivariable logistic regression 
and negative binomial regression modelling. Separate models were used to evaluate 
the impact of each chronic condition and the impact of MCCs. Results: Cancer 
survivors were more likely to have MCCs, with 12.4% reporting ≥ 4 chronic conditions 
compared to 9.3% of individuals without a history of cancer. Medical expenditures 
for cancer survivors with other chronic conditions, particularly those with MCCs 
were higher than among cancer survivors without any of the chronic conditions 
studied. The largest increase in medical expenditures was associated with heart 
disease ($4,287) and stroke ($4,210). Having ≥ 4 chronic conditions was associated 
with increased expenditures of $9,082 per cancer survivor. Lost productivity was 
greater among cancer survivors with other chronic conditions. The largest increase 
in lost productivity was associated with stroke ($4,144) and arthritis ($3,426). Having 
≥ 4 chronic conditions was associated with increased lost productivity of $9,245 
per cancer survivor. ConClusions: Chronic conditions, especially the presence 
of MCCs, are associated with higher medical expenditures and lost productivity 
among cancer survivors. Efforts to reduce the health and economic burden caused 
by chronic conditions among cancer survivors are important given their substantial 
impact on medical expenditures and lost productivity.
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objeCtives: Regression models are the multivariable analytical method of choice 
for epidemiologists and statisticians. It is widely recognized that these models may 
suffer from over-fitting, where the sample estimates fail to generalize to other sam-
ples. Systematic approaches to minimize over-fitting are seldom adopted and there 
is a reluctance to hold data back for independent assessment of model performance. 
This study assesses penalized regressions for reducing over-fitting, cross-validation 
on training data for estimating over-fitting, and the extent to which over-fitting 
produces misleading conclusions. Methods: Data were extracted from the IMS 
PharMetrics Plus US medical claims database for patients with Multiple Sclerosis 
receiving one of two treatments. Cohorts were matched using propensity scoring, 
producing 3,348 matched pairs. The probability of relapse and persistence were 
estimated using standard, stepwise and (LASSO) penalized logistic regressions. 
Over-fitting was measured as the difference between the Area Under Curve (AUC) 
for training and test data and additionally estimated using cross-validation on 
training data alone. Results: Penalized logistic regressions greatly reduced over-
fitting compared to standard and stepwise alternatives, irrespective of the choice 
of response variable and degrees of freedom: for example, modelling relapse with 
50% of the data used for training and 50% used for testing showed overfitting of 
9.9% with standard, 8.0% with stepwise and 3.9% with penalized logistic regression. 
Cross-validation provided reasonable approximations for over-fitting; estimated 
over-fitting for the above standard logistic model was 10.4%. Over-fitting inflated 
the estimated treatment effect by 25% (OR= 2.03 vs. 1.64; standard logistic model 
vs. penalized model). ConClusions: Penalized logistic regression models had 
substantially lower over-fitting. Moreover, good estimates of over-fitting can be 
derived without withholding data. Both penalized regressions and cross-validation 
are straightforward to implement in most statistical packages and greater adoption 
of these methods is encouraged to ensure more reliable estimates of risk factors.
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objeCtives: A state transition model (STM) and a discrete event simulation (DES) 
were developed to evaluate the health outcomes associated with antiplatelet treat-
ments for secondary prevention of thrombotic events for patients with a recent 
myocardial infarction (MI) in the UK. Methods: The STM and DES were devel-
oped with similar assumptions about which events altered risk. In both models, 
results were compared between the vorapaxar plus standard care (VOR) and the 
standard care (SC) arms. Individual patient characteristics at baseline from the quali-
fying MI cohort of TRA 2°P-TIMI 50 trial were used to define patient profiles in both 
models; risk equations developed from the trial were used to estimate MI, stroke, 
and cardiovascular-related death risk. Bleeding event risks, case fatality rates, non-
cardiovascular mortality, and utilities were taken from published studies or UK sta-
tistics. Results: In the base case, for the VOR and SC arms, the DES predicted 13.93 
and 13.70 quality-adjusted life years (QALYs), respectively, versus 12.27 and 11.81 in 
the STM. The DES predicted 0.268 MIs, 0.140 strokes, and 0.318 CV-deaths per patient 
in the VOR arm, and 0.279 MIs, 0.145 strokes, and 0.325 CV-deaths per patient in the 
SC arm. The STM predicted 0.226 MIs, 0.132 strokes, and 0.417 CV-deaths per patient 
in the VOR arm, and 0.234 MIs, 0.136 strokes, and 0.435 CV-deaths per patient in the 
SC arm. ConClusions: Although these two models have very different structures, 
both estimated similar outcomes. The DES predicted more MI and stroke events than 
the STM, as patients can have multiple events in a short time frame rather than one 
event per model cycle. While both approaches are valid, the DES technique offers 
greater flexibility through its ability to consider many risk-changing events without 
“exploding” health states and to track changes in risk factors more efficiently.
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objeCtives: Clinical efficacy or effectiveness (the “E”) is one driver of cost-effec-
tiveness analysis (CEAs). The type of “E” used in each CEA depend on the objectives 
and corresponding data sources. Applying different types of the “E” might affect 
CEA conclusions, but little is known. We aim to test the association of type of “E” 
and cost-effectiveness conclusions using asthma CEAs as an example. Methods: 
A systematic review was performed with 5 electronic databases from 2009 to 2014. 
All CEA studies evaluating asthma medication(s) and reporting incremental cost 
per quality-adjusted life year (QALY) were included. The “E” which was derived from 
an explanatory randomized controlled trial(s) (RCT) or meta-analysis of RCTs was 
defined as efficacy, while the “E” from a pragmatic RCT(s), an observational study, or 
registry was classified as effectiveness. Three times the World Health Organization 
Gross Domestic Product was used to determine a cost-effectiveness willingness-to-
pay threshold per QALY gained. Logistic regression was used to associate type of “E” 
and cost-effectiveness conclusions. Results: A total of 17 CEAs were included. Nine 
studies (52.9%) used efficacy evidence, while 8 studies (47.1%) used effectiveness 
evidence. Ten studies (58.8%) were modeling-based studies, while 7 studies (41.2%) 
were CEA-alongside-clinical trials. The “E” of 5 studies (29.4%) were derived from 
explanatory RCTs, 4 studies (23.5%) from meta-analysis of RCTs, 4 studies (23.5%) 
